Pharmaceuticals, Biotechnology and Life Sciences
VANCOUVER, British Columbia–(BUSINESS WIRE)–#eclips–Evasc Neurovascular is proud to announce its successful application to France’s Ministry of Health (Haute Autorité de la Santé, HAS) Forfait Innovation (FI) program for the eCLIPs™ device, publishe…
WALTHAM, Mass.–(BUSINESS WIRE)–Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize coronaviruses, today announced that Tillman Gerngross, Ph.D., chief executive officer, and Jane Henderson, chi…
WALTHAM, Mass.–(BUSINESS WIRE)–Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize coronaviruses, today announced that Tillman Gerngross, Ph.D., chief executive officer, and Jane Henderson, chi…
WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2020 fourth quarter and full year financial results on Tuesday, March 2, 2021, before the mar…
WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2020 fourth quarter and full year financial results on Tuesday, March 2, 2021, before the mar…
HERCULES, Calif.–(BUSINESS WIRE)–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO; Andrew Last, Executive Vice Presiden…
— Data validated efficacy and safety and informs dosing strategy for Phase 3 program
— Achieved key co-primary endpoint on efficacy, with 500U dose demonstrating statistically significant difference from placebo in the Modified Ashworth Score (MAS) i…
Fourth quarter and full year 2020 total product and service revenue of $10.2 million and $13.3 million, respectively
First full quarter of RHA® Collection of dermal fillers revenue of $10.0 million
Exited 2020 with over $200 million in annualiz…
BRIDGEWATER, N.J.–(BUSINESS WIRE)–Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that its management team will virtually attend the following investor conferences:
Raymond James Institutional Investors Conference
March 1, …
Fourth quarter and full year 2020 total product and service revenue of $10.2 million and $13.3 million, respectively
First full quarter of RHA® Collection of dermal fillers revenue of $10.0 million
Exited 2020 with over $200 million in annualiz…